SUZUKEN (9987) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The Company reported higher revenue but lower operating income, while net income increased, supported by gains on the sale of investment securities. Revenue was ¥1,885.63B (+2.6% YoY), operating income was ¥27.23B (-8.6% YoY), ordinary income was ¥29.31B (-5.2% YoY), and net income was ¥31.02B (+1.1% YoY). The primary factor behind the decline in operating income was deteriorating profitability in the core Pharmaceutical Wholesale Business. The increase in net income was supported by a temporary boost from extraordinary income of ¥15.23B, primarily comprising ¥14.95B in gains on the sale of investment securities.

Factors Affecting Performance

【Revenue】Revenue increased 2.6% YoY to ¥1,885.63B. The core Pharmaceutical Wholesale Business, which accounted for 96.7% of total revenue, led the overall growth with a 2.7% increase. The Specialty Pharmaceutical Distribution Contract Business recorded the highest growth at +7.2%, while the Healthcare Product Development Business (-2.2%) and Regional Medical and Nursing Care Support Business (-0.8%) reported declines in revenue.

【Profit and Loss】Operating income was ¥27.23B (-8.6% YoY), and the operating margin was 1.4%, down approximately 18bp from the same period of the previous year. The primary factor was a 9.5% decline in segment profit in the Pharmaceutical Wholesale Business despite higher revenue, suggesting pressure from pricing, procurement terms, and the cost structure. Ordinary income was limited to ¥29.31B (-5.2% YoY); however, the recognition of extraordinary income of ¥15.23B, including ¥14.95B in gains on the sale of investment securities, lifted profit before tax to ¥44.26B, enabling net income to increase to ¥31.02B (+1.1% YoY). Overall, the Company recorded higher revenue but lower profit, and the increase in net income resulted from temporary gains on asset sales rather than improvements in the core business.

Segment Analysis

The Pharmaceutical Wholesale Business generated external-customer revenue of ¥1,782.11B (+2.7% YoY) and segment profit of ¥22.79B (-9.5% YoY), making it the core business and accounting for 83.9% of total reported segment profit of ¥27.16B. Profit declined despite higher revenue, making this the primary cause of the Company-wide decline in operating income. The Healthcare Product Development Business reported revenue of ¥8.95B (-2.2% YoY) and profit of ¥1.78B (-28.0% YoY), representing a significant decline in profit. The Regional Medical and Nursing Care Support Business secured higher profit of ¥0.79B (+25.5% YoY) despite revenue of ¥70.41B (-0.8% YoY). The Specialty Pharmaceutical Distribution Contract Business reported revenue of ¥5.31B (+7.2% YoY) and profit of ¥0.87B (+36.3% YoY), recording the strongest growth through higher revenue and profit, although its profit margin on a total-revenue basis remained low at approximately 0.3%. The Medical-Related Services and Other Business performed steadily, with revenue of ¥18.84B (+2.8% YoY) and profit of ¥0.93B (+11.8% YoY).

Key Financial Indicators

【Profitability】The operating margin was 1.4%, down approximately 18bp from the same period of the previous year, reflecting a structure in which gross profit margin of 7.7% is substantially compressed after deduction of SG&A expenses. The net profit margin was 1.6%; however, this figure includes gains on the sale of investment securities and therefore appears higher than the recurring earnings power, which warrants caution.【Cash Flow Quality】Accounts receivable were ¥616.02B, accounting for 47.1% of total assets, while annualized days sales outstanding were approximately 89 days, indicating a prolonged collection period.【Investment Efficiency】Annualized ROE was 7.7%, comprising a net profit margin of 1.6%, annualized total asset turnover of 1.442 times, and financial leverage of 3.23 times, indicating that the low profit margin is supplemented by asset turnover and leverage.【Financial Soundness】The equity ratio was 31.0% (down from 36.6% in the previous year), while the current ratio was 118.8% and the quick ratio was 99.2%, both approximately at the 100% level. The D/E ratio was 2.23 times, indicating a high degree of debt utilization. Interest paid was small at ¥0.03B, leaving substantial capacity to bear interest costs.

Cash Flow Analysis

Although the cash flow statement has not been directly disclosed, cash flow trends are analyzed based on changes in the balance sheet. Cash and deposits increased substantially to ¥194.72B from ¥102.66B in the same period of the previous year, while total assets expanded by approximately ¥193.6B from the previous year to ¥1,307.46B. Accounts receivable (+¥92.0B), inventories (+¥25.8B), and accounts payable (+¥191.9B) all increased. The increase in accounts payable was the primary source of funding for the increase in assets, indicating an expansion in working capital. Because a substantial portion of net income of ¥31.02B was derived from extraordinary income, actual cash generation from operating activities is likely smaller than the level of net income. The expansion of accounts receivable and the associated lengthening of the collection period should be closely monitored for their potential impact on future liquidity.

Earnings Quality

The increase in net income to ¥31.02B was driven by extraordinary income of ¥15.23B, primarily consisting of ¥14.95B in gains on the sale of investment securities, while ordinary income declined 5.2% YoY; therefore, the increase did not result from improved core-business profitability. Of profit before tax of ¥44.26B, net extraordinary gains and losses amounted to ¥14.95B, indicating that recurring profit before tax excluding this item was approximately ¥29.3B. Of non-operating income of ¥2.38B, dividends received accounted for ¥1.19B. Although this is recurring in nature, its scale is small. Accounts receivable accounted for 47.1% of total assets, and annualized days sales outstanding were approximately 89 days. This indicates that it takes a long time for earnings to convert into cash, suggesting that some caution is warranted regarding earnings quality from an accrual perspective.

Earnings Forecast and Guidance

Progress against the full-year Company forecast was 76.4% for revenue, 81.0% for operating income, 83.5% for ordinary income, and 94.6% for net income (forecast EPS: ¥455.13). Revenue, operating income, and ordinary income all exceeded standard progress levels adjusted for seasonality (approximately 75%), indicating steady progress toward the full-year plan. However, the high progress rate for net income was substantially boosted by gains on the sale of investment securities; it is therefore appropriate to assess performance based on operating income and ordinary income, which better reflect progress in the core business. The full-year forecast anticipates declines of 9.5% in operating income and 9.6% in ordinary income YoY, suggesting that profitability pressure is expected to continue through the second half of the fiscal year.

Shareholder Returns

The Q2 dividend was ¥50 per share, and the full-year Company forecast calls for an annual dividend of ¥100. Based on forecast full-year net income of ¥32.80B, the forecast payout ratio is approximately 21.5%, substantially below the 60% level, indicating a low dividend burden relative to accounting profit. Because data concerning share repurchases has not been disclosed, this report evaluates only the payout ratio.

Risk Factors

1. Deteriorating profitability in the core business: The Pharmaceutical Wholesale Business is the core business, accounting for 83.9% of reported segment profit. Segment profit declined 9.5% despite a 2.7% increase in revenue, creating a structure in which the profitability of this business determines Company-wide earnings.

2. Accounts receivable collection and financial leverage: Annualized days sales outstanding were approximately 89 days, and the D/E ratio was 2.23 times, both above typical levels. A key financial point to monitor is whether short-term settlements, centered on accounts payable of ¥827.67B, can be financed smoothly through accounts receivable collections and cash and deposits.

3. Divergence in earnings quality: The increase in net income was heavily dependent on gains of ¥14.95B from the sale of investment securities, while both operating income and ordinary income declined. The divergence between core-business earnings power and accounting net income will be an important issue in evaluating future performance.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

The Company's profitability is below the industry median for both operating margin and net profit margin, placing it at a relatively low-margin level within the industry.

Growth and Capital Efficiency

The revenue growth rate is below the industry median, and the pace of revenue growth is relatively moderate within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Although revenue increased, the operating margin declined approximately 18bp YoY. Improvement in the profitability of the Pharmaceutical Wholesale Business, which accounts for more than 80% of reported segment profit, will be the central issue in evaluating future performance trends.

2. Progress rates for operating income and ordinary income against the full-year plan (81.0% and 83.5%, respectively) exceed standard levels; however, the 94.6% progress rate for net income was substantially boosted by gains on the sale of investment securities and must be assessed separately from progress in the core business.

3. Annualized days sales outstanding were approximately 89 days, and the D/E ratio was 2.23 times. Working capital management, including the balance between accounts receivable collection and accounts payable settlement, will be a key financial area to monitor.

Theoretical Share Price (Reference Value)

Sensitivity: ¥5,613–¥5,947 at ±1% for the cost of equity, and ¥5,771–¥5,779 at ±0.1 for ω.

Notes:

• Because net income progress against the full-year forecast (95%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with leading progress tend to outperform forecasts; adjustments may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Suzuken’s FY2026 Q3 result was operationally softer despite a modest increase in reported net income. Revenue rose 2.6% YoY to ¥1,885.6bn, led by continued expansion in the core pharmaceutical wholesaling business and specialty pharmaceutical distribution services. Operating income declined 8.6% YoY to ¥27.2bn, materially underperforming revenue growth. Ordinary income fell 5.2% to ¥29.3bn. Gross profit decreased 1.4% to ¥144.6bn even as revenue expanded, indicating a weaker gross-profit capture on sales growth. The gross margin contracted by approximately 31bp YoY to 7.7%. The operating margin fell by approximately 18bp to 1.4%, reflecting the gross-profit decline while SG&A was broadly stable at ¥117.4bn. Net income attributable to owners rose 1.1% to ¥31.0bn, but this did not represent an improvement in recurring earnings. A ¥15.0bn gain on sales of investment securities, included in extraordinary income, was the principal support for profit before tax of ¥44.3bn. This gain represented about 48% of reported net income and more than offset the ¥2.6bn decline in operating income. Accordingly, earnings quality is weaker than the headline net-income growth suggests. The annualized ROE of 10.2% is acceptable on a headline basis, but it is supported by high financial leverage and non-recurring securities gains rather than improving operating profitability. The pharmaceutical wholesale business remains the clear core business, accounting for 83.7% of external revenue and 83.9% of segment profit, but its segment profit fell 9.5% YoY. Balance-sheet liquidity remains adequate, with a 118.8% current ratio and cash increasing to ¥194.7bn. However, the 2.23x D/E ratio exceeds the 2.0x risk threshold, while receivable days of 89 indicate substantial working-capital intensity. Full-year guidance implies that sales, operating income and ordinary income are progressing ahead of the standard 75% Q3 pace, whereas net-income progress is exceptionally high because of the investment-security gain. The key implication into year-end is that the company needs stabilization in wholesale margins and segment profitability for earnings growth to be sustainable after excluding asset-sale gains.

Profitability Analysis

The annualized DuPont ROE is 10.2%, comprising a 1.6% net profit margin, 1.923x asset turnover and 3.23x financial leverage. Asset turnover is strong for a pharmaceutical wholesaler, reflecting the high-volume, low-margin distribution model. Financial leverage is the principal enhancer of shareholder returns, as the 3.23x leverage factor elevates ROE despite a thin net margin. The weakest component is profitability: EBIT margin was only 1.4%, below the 5% general benchmark and down about 18bp YoY. Gross margin decreased to 7.7% from approximately 8.0% in the prior-year period, a contraction of around 31bp. This gross-margin compression was the main reason operating income declined 8.6% despite 2.6% revenue growth. SG&A declined only 0.4% YoY, so cost control partially cushioned the decline but was insufficient to offset weaker gross profit. The core pharmaceutical wholesaling segment generated ¥1,782.1bn of external revenue, up 2.7% YoY, but segment profit fell 9.5% to ¥22.8bn; its segment margin therefore declined to 1.25% from 1.42%. Healthcare product development revenue declined 2.2% to ¥9.0bn and segment profit fell 28.0% to ¥1.8bn, reducing its margin to 19.8% from 26.9%. Regional healthcare and nursing-care support revenue declined 0.8% to ¥70.4bn, while segment profit increased 25.5% to ¥0.8bn, lifting its margin to 1.12%. Specialty pharmaceutical distribution services delivered the strongest operational improvement, with external revenue up 7.2% to ¥5.3bn and segment profit up 36.3% to ¥0.9bn; its margin improved to 16.4% from 12.9%. Medical-related services revenue increased 2.8% to ¥18.8bn and segment profit rose 11.8% to ¥0.9bn, raising margin to 4.93% from 4.53%. Dividend income of ¥1.2bn and equity-method income of ¥0.3bn modestly supported non-operating earnings, but the major difference between ordinary income and net income was the non-recurring ¥15.0bn securities-sale gain. The tax burden ratio of 0.701 and effective tax rate of 29.9% were broadly normal. Interest expense was only ¥0.03bn and interest coverage was 850.9x, so funding cost is not currently constraining profitability.

Growth Assessment

Revenue growth of 2.6% indicates continued top-line expansion, but the composition points to limited operating leverage. Pharmaceutical wholesaling, the core business, added ¥46.8bn of external revenue YoY but lost ¥2.4bn of segment profit. This suggests that revenue expansion is not currently translating into improved unit economics. Specialty pharmaceutical distribution services is the most attractive growth contributor, combining 7.2% external-revenue growth with 36.3% segment-profit growth. Medical-related services also produced positive revenue and profit growth, although its absolute contribution remains modest. Regional healthcare and nursing-care support improved profitability despite marginally lower revenue, indicating favorable cost or mix effects. Healthcare product development was the weakest non-core segment, with both revenue and profit declining. Full-year sales guidance is ¥2,468.0bn, and Q3 cumulative revenue progress is 76.4%, slightly above the standard 75% Q3 run rate. Operating-income progress is 81.0% against the ¥33.6bn full-year forecast, 6.0 percentage points ahead of the standard seasonal benchmark. Ordinary-income progress is 83.5% against the ¥35.1bn forecast, also ahead of the standard pace. Net-income progress is 94.6% against the ¥32.8bn forecast, far above the 75% standard pace and primarily explained by the securities-sale gain. The forecast therefore appears operationally achievable on the reported Q3 run rate, but its implied full-year operating-income decline of 9.5% YoY underscores that management is not forecasting a margin recovery. Revenue sustainability depends on maintaining distribution volumes, specialty-drug handling growth and disciplined pricing in the wholesale business. Profit sustainability depends more critically on restoring gross-margin performance, as non-recurring investment gains cannot be treated as a recurring earnings engine.

Financial Health

Liquidity is adequate but not abundant. Current assets of ¥1,044.0bn exceeded current liabilities of ¥878.5bn, producing working capital of ¥165.5bn and a current ratio of 118.8%. The current ratio is above 1.0x and therefore does not signal an immediate maturity mismatch. The quick ratio was 99.2%, just below 1.0x, indicating that liquidity is heavily dependent on timely collection of receivables. Cash and deposits increased ¥92.1bn YoY to ¥194.7bn, providing a meaningful liquidity buffer. However, trade receivables accounted for 47.1% of total assets and increased ¥91.9bn YoY to ¥616.0bn. Inventories accounted for 13.2% of total assets and increased ¥25.8bn YoY to ¥172.4bn. Accounts payable rose by a larger ¥191.9bn YoY to ¥827.7bn, which funded much of the increase in operating working capital and cash. The D/E ratio of 2.23x exceeds the 2.0x warning threshold and must be treated as a high-leverage alert. The root cause is the liability-heavy nature of the distribution model, particularly the ¥827.7bn trade-payables balance, relative to ¥405.2bn of equity. This structure is common to some extent in pharmaceutical wholesale, where large product flows create substantial payables and receivables, but it heightens dependence on uninterrupted supplier credit and efficient cash conversion. The impact is that a deterioration in collections, supplier payment terms or inventory liquidity could pressure financing flexibility despite the currently strong interest coverage. Total equity declined 0.5% YoY to ¥405.2bn while total assets increased 17.4% to ¥1,307.5bn, reducing the capital adequacy ratio to 31.0% from 36.6%. Goodwill was immaterial at ¥0.05bn, equivalent to virtually 0% of equity and assets, leaving no material acquisition-related impairment dependency. Intangible assets were also modest at 0.9% of total assets. Treasury stock increased in absolute value by ¥20.2bn to negative ¥20.7bn, consistent with sizable repurchases or other capital actions and reducing equity available as a loss-absorption buffer.

Notable B/S Changes

Cash and deposits: +¥92.1bn (+89.7%) to ¥194.7bn - strengthened immediate liquidity, although the increase coincided with a substantial rise in trade payables. Accounts receivable: +¥91.9bn (+17.5%) to ¥616.0bn - receivables remain the largest asset category at 47.1% of total assets; combined with 89-day DSO, collection efficiency is a key monitor. Accounts payable: +¥191.9bn (+30.2%) to ¥827.7bn - the major contributor to liability growth and a key source of working-capital funding; increases dependence on supplier-credit terms. Treasury stock: -¥20.2bn to negative ¥20.7bn - indicates a substantial increase in treasury-share holdings, reducing equity and requiring monitoring alongside dividend commitments. Total assets: +¥193.8bn (+17.4%) to ¥1,307.5bn - asset expansion materially exceeded equity growth, contributing to the decline in the capital adequacy ratio to 31.0% from 36.6%. Goodwill: -¥0.009bn (-64.3%) to ¥0.005bn - immaterial balance with no meaningful M&A-related impairment exposure.

Cash Flow Quality

Reported earnings contain a substantial non-recurring component: the ¥15.0bn gain on sales of investment securities accounted for most of the increase in net income. Profit before tax exceeded ordinary income by ¥14.9bn, almost entirely reflecting extraordinary gains net of extraordinary losses. The gain on sale of investment securities increased from ¥10.9bn in the prior-year period to ¥15.0bn, so the additional ¥4.0bn of gains more than explains the ¥0.3bn YoY increase in net income. Consequently, reported net income of ¥31.0bn materially overstates recurring operating performance relative to operating income of ¥27.2bn. Working-capital intensity is high, with receivables of ¥616.0bn and inventories of ¥172.4bn. The 89-day DSO quality alert is a material efficiency concern because it exceeds the 60-day threshold. Its root cause is likely the combination of a large institutional and pharmacy customer base with the inherently high transaction volumes of pharmaceutical distribution. While extended collection periods can be characteristic of this industry, the 89-day level raises sensitivity to reimbursement cycles, customer credit conditions and collection discipline. The impact is that even modest slowing in collections can consume liquidity because receivables represent nearly half of total assets. The ¥191.9bn increase in payables exceeded the combined ¥117.7bn increase in receivables and inventories, which has supported balance-sheet liquidity during the period. This reliance on trade payables makes supplier terms and inventory-turn discipline important indicators of underlying cash-conversion resilience. Comprehensive income of ¥25.1bn was below net income because valuation differences on securities reduced other comprehensive income by ¥5.5bn.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥50 per share. The disclosed Q2-only payout ratio was 11.6% of Q3 cumulative net income, indicating limited interim earnings distribution. Full-year dividend guidance is ¥100 per share, implying a ¥50 year-end dividend if the interim payment is maintained. Based on forecast EPS of ¥455.13, the implied full-year dividend payout ratio is approximately 22.0%. This is well below the 60% sustainability benchmark and provides substantial accounting earnings coverage. The forecast dividend commitment is approximately ¥7.2bn based on 72.17 million issued shares, compared with forecast profit attributable to owners of ¥32.8bn. Dividend sustainability is therefore supported by the forecast payout burden and the company’s ¥194.7bn cash balance. However, reported Q3 profit includes a substantial gain on sale of investment securities, so recurring operating profit should be monitored as the more relevant source of long-term dividend capacity. The increase in treasury stock by ¥20.2bn indicates that capital returns may also include share repurchases or related treasury-share transactions. If repurchases are confirmed as a capital return, the appropriate assessment would be total return ratio rather than dividend payout ratio alone. The balance-sheet leverage profile means capital returns should remain consistent with preserving liquidity for the working-capital-intensive wholesale operation.

Risk Assessment

Business risks include Pharmaceutical wholesale margin risk: the core wholesale segment’s revenue rose 2.7% YoY but segment profit fell 9.5%, demonstrating sensitivity to purchase-price terms, reimbursement pricing, customer mix and competitive pricing., Low operating efficiency: the 1.4% EBIT margin is below the 5% alert threshold. The root cause is the structurally low-margin distribution model compounded by current gross-margin compression. The impact is that modest cost inflation or pricing pressure can have a disproportionate effect on earnings., Low gross margin: gross margin fell to 7.7% from about 8.0%. This is below the stated 20% general benchmark, although low gross margins are structurally typical for high-volume pharmaceutical wholesalers. The relevant concern is the direction of change and the resulting decline in operating income., Receivables and reimbursement-cycle risk: DSO of 89 days exceeds the 60-day alert threshold, increasing exposure to delayed collections and customer-credit stress., Specialty-drug execution risk: specialty pharmaceutical distribution is growing rapidly and has high segment margins, but its larger internal transaction volume increases the importance of compliance, cold-chain logistics and service-quality execution..

Financial risks include High leverage: the 2.23x D/E ratio exceeds the 2.0x warning threshold. The liability base is dominated by trade payables, which is partly industry-structural, but it leaves the balance sheet reliant on supplier-credit continuity and receivables collection., Liquidity concentration: the quick ratio of 99.2% is marginally below 1.0x, and liquid resources are substantially tied to trade receivables rather than cash alone., Capital-buffer dilution: the capital adequacy ratio declined to 31.0% from 36.6% as assets expanded faster than equity., Securities-market exposure: valuation differences on securities reduced comprehensive income by ¥5.5bn, and the company realized a large securities-sale gain during the period..

Key concerns include Highest priority: restoring wholesale gross margin and segment-profit conversion; without this, top-line growth will not produce recurring earnings growth., High priority: maintaining collection discipline and supplier-payment flexibility given ¥616.0bn of receivables, ¥827.7bn of payables and 89-day DSO., High priority: distinguishing recurring earnings from securities-sale gains, which lifted Q3 net income despite lower operating and ordinary income., Moderate priority: preserving equity and liquidity buffers while conducting shareholder returns, given the increased treasury-stock balance and elevated D/E ratio..

Investment Implications

Key takeaways include Revenue growth remained positive at 2.6% YoY, but operating income declined 8.6% as gross margin compressed by about 31bp., Core pharmaceutical wholesaling remains the earnings base, but its ¥22.8bn segment profit was down 9.5% YoY despite higher revenue., Specialty pharmaceutical distribution services was the strongest segment, with segment profit up 36.3% YoY and margin expanding to 16.4%., Net income growth of 1.1% YoY was supported by a ¥15.0bn gain on sales of investment securities rather than recurring operating improvement., Annualized ROE of 10.2% is supported by high asset turnover and 3.23x financial leverage; the 1.6% net margin remains thin., Liquidity is adequate, but elevated leverage, 89-day DSO and a quick ratio just below 1.0x require continued working-capital discipline., The implied full-year dividend payout ratio of about 22% is modest relative to forecast earnings..

Metrics to watch include Core pharmaceutical wholesaling segment margin and profit conversion, Gross margin and consolidated EBIT margin, Specialty pharmaceutical distribution revenue and segment-profit growth, Receivable days, receivables growth and collection performance, Trade-payables trend and current/quick ratios, D/E ratio and capital adequacy ratio, Scale of realized investment-security gains relative to recurring profit, Progress versus full-year operating-income guidance.

Regarding relative positioning, Suzuken exhibits the characteristic profile of a pharmaceutical wholesaler: high sales volume and asset turnover, structurally narrow margins, and substantial trade receivables and payables. Its annualized 10.2% ROE is respectable, but the return profile is less robust than it appears because it relies on leverage and non-recurring investment gains while core operating margins are declining. The specialty pharmaceutical distribution business provides an attractive higher-margin growth vector, but it remains small relative to the wholesale segment.